FASEB J: Reducing early encephalitis may delay progression of Alzheimer's disease

May 12, 2020 /
PRNewswire
BIOON//In a new animal study of Alzheimer's disease, researchers have found that reducing neuroinflammation in the brain can slow progressosts before memory problems and cognitive impairments occurThe new findings point to the importance of developing treatments for the early stages of the disease2011, the National Institute on Aging updated thecriteria fordiagnosis of Alzheimer's disease to reflect its conductThe standard adds a preclinical phase during which the brain is changing, but the patient is still without symptoms and therefore does not know his or her conditionBiomarker maps could eventually be used to identify people in the early stages of the disease who may benefit from early treatmentimage source: Giorgia Menegoni, Sapienza, University of Rome, who led the research team and associate professor of pharmacology and toxicology at the University of Rome, caterina Scuderi said: "In the early stages of the disease, when cell and molecular changes have been triggered but the main damage to the brain has not yet occurred intervention, can provide a way to reduce the number of people with complete dementia." However, there have been few studies of treatment strategies prior to the onset of symptoms in animal experimentsScuderi plans to present the study at the American Anatomy Society's annual meeting in San Diego this yearAlthough themeeting scheduled to coincide with the 2020 Conference on Experimental Biology was canceled due to the outbreak of COVID-19, the team's summary was published this month in the journal FASEBresearchers have designed an animal study to better understand the role of neuroinflammation in the pre-Alzheimer's stages, which may be the best time to treat interventionsThe results suggest that it may be beneficial to rebalance nerve inflammation in animals and to alter the parameters of nerve inflammation"Our results help prove that neuroinflammation in Alzheimer's disease is an extremely complex phenomenon that can change as the disease progresses and depends on factors such as affected brain regions," Scuderi said We hope these findings will prompt scientists to further investigate nerve inflammation in the early stages of the disease, as this could be an important pharmacological target (biovalleybioon.com) Reference: ReducingearlybrainbrainAlzheimer's Progression
Caterina Scudeilltal.
Neuroifin Alzheimer's Disease: Friendor Foe? TheFASEBJournal.2020.https://doi.org/10.1096/fasebj.2020.34.s1.00381